Recent News

• 07.30.2026 - INOVIO Announces Pricing of $20.0 Million Public Offering
• 07.29.2026 - INOVIO Announces Proposed Public Offering
• 01.09.2025 - INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments
• 12.13.2024 - INOVIO Announces Pricing of $30 Million Public Offering
• 12.12.2024 - INOVIO Announces Proposed Public Offering
• 12.12.2024 - INOVIO Announces Proposed Public Offering
• 12.03.2024 - New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial
• 11.14.2024 - INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights
• 11.13.2024 - Immunology Data Shows INOVIO’s INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial
• 11.13.2024 - Immunology Data Shows INOVIO’s INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

Recent Filings

• 07.31.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.31.2026 - 8-K Current report
• 07.31.2026 - EX-99.1 EX-99.1
• 07.30.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.29.2026 - 8-K Current report
• 07.29.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 07.10.2026 - EFFECT Notice of Effectiveness
• 07.02.2026 - S-3 Registration statement under Securities Act of 1933
• 05.26.2026 - S-8 Securities to be offered to employees in employee benefit plans
• 05.21.2026 - 4 Statement of changes in beneficial ownership of securities